Esperion Therapeutics Advances PSC Drug Progress with ACLY inhibition Strategy

Primary sclerosing cholangitis (PSC) is a chronic, progressive liver disease with limited treatment options. Esperion Therapeutics is forging a new path in PSC drug development, focusing on inhibiting the enzyme ATP-citrate lyase (ACLY) as a potential therapeutic strategy. This article delves into Esperion’s approach, the science behind ACLY inhibition, and the ⁢company’s plans for future clinical trials.

Understanding Primary Sclerosing Cholangitis and the Need for New Therapies

PSC is characterized by inflammation and fibrosis of the bile ducts, ultimately leading to⁤ cirrhosis, liver failure, and increased risk of cholangiocarcinoma ⁣(bile duct⁣ cancer). The disease affects⁣ men more frequently enough than women and typically presents between the ages of⁤ 30 and 50.Currently, the only definitive treatment for PSC⁢ is liver⁤ transplantation, highlighting the urgent need for effective medical therapies that can slow disease progression and improve patient outcomes.

The underlying cause ⁤of PSC remains unknown,but it is ⁢strongly associated with⁤ inflammatory bowel disease (IBD),especially ulcerative‍ colitis. Existing treatments primarily focus on managing symptoms and complications, rather than addressing the root cause of the disease. This is where Esperion’s innovative approach comes into play.

Esperion’s ACLY Inhibition Strategy: A Novel Approach to PSC Treatment

Esperion Therapeutics is pioneering⁢ a novel approach to PSC treatment by targeting ACLY, an enzyme crucial in fatty acid synthesis. Research suggests that ACLY plays a critically important role in⁣ the pathogenesis of PSC by contributing to inflammation and fibrosis within the liver. By⁣ inhibiting ACLY,⁣ Esperion aims to reduce these ⁤damaging processes and perhaps halt or slow the progression of the disease.

“We believe that ACLY‍ inhibition represents a promising new therapeutic avenue for PSC,” explains ⁣Stephen Pinkosky, phd, Vice President of ⁤Drug Revelation and Development at Esperion. “Our preclinical studies have demonstrated that inhibiting ACLY can ‍considerably reduce inflammation and fibrosis in‍ models of PSC.”

The Science Behind ACLY Inhibition in PSC

ACLY catalyzes the first step in de novo fatty acid synthesis, a process that provides building blocks for cell membranes and signaling molecules. In PSC, increased ACLY activity is linked to the accumulation of lipids and the activation of inflammatory pathways.This leads to ‍the production of ‍pro-inflammatory cytokines and the deposition of collagen, ultimately driving fibrosis.

Esperion’s ACLY inhibitor aims to disrupt this cycle by reducing fatty acid synthesis, thereby dampening inflammation and preventing further fibrosis. Preclinical studies have shown that the inhibitor effectively reduces ACLY activity in liver cells and attenuates key markers of⁢ PSC pathology.

Advancing Towards Clinical Trials: Safety, Biomarkers, and Future Directions

Esperion is currently conducting a series of regulated preclinical ⁤safety studies to ⁢thoroughly evaluate the potential of its ACLY inhibitor. These studies ⁣are designed to assess the drug’s safety profile and identify any potential ⁢adverse effects.Simultaneously, the team is working to refine its understanding of ACLY’s precise role in PSC, exploring the complex interplay between ACLY inhibition and downstream effects on liver‍ inflammation and fibrosis.

A critical component of Esperion’s ⁢strategy is the development of robust biomarkers.These biomarkers will be essential for measuring ACLY inhibition⁤ and⁢ assessing the⁤ drug’s impact on PSC in future clinical trials.

“Our⁣ Esperion team is also focused on discovering and developing biomarkers,⁣ which will help us understand how well the drug is inhibiting ACLY in future clinical studies and whether it is indeed having the expected downstream effects on PSC,” pinkosky states.

The company is actively working to identify biomarkers that can accurately reflect ACLY⁢ activity and the resulting changes in liver pathology. This will allow for more⁣ precise⁣ monitoring of drug efficacy and personalized treatment approaches.

“There is much work left to be done,” Pinkosky acknowledges, “but we’re quite optimistic about where this ‍effort will lead.”

Meet Stephen Pinkosky

stephen pinkosky, PhD, has served ⁢as Vice President of Drug Discovery and Development at Esperion as August 2024. Prior to assuming⁢ his current role, Dr Pinkosky held positions of increasing ⁢responsibility at the company, which he joined in 2008. Before joining Esperion, he worked as a Scientist in the Research and Development Department at Aastrom Biosciences, Inc., a Scientist in Vascular Biology⁤ at Esperion Therapeutics, a Pfizer ⁣Inc. company, and as ⁢an Associate Scientist in Inflammation ⁣Pharmacology at Pfizer Global Research and Development.

With more than⁣ 20 years’ experience in ⁤the pharmaceutical industry, Dr Pinkosky specialises